Home › Companies › OVID

Ovid Therapeutics Inc.

OVID Rare disease Lead: Phase 1 4 Biotech Distilled articles ↓

Neurology Small Molecule

Most recent annual filing: 2026-03-15

Pipeline (6 active programs)

OV329

Small Molecule Target: GABA-aminotransferase, GABA-AT

Drug-Resistant Focal Onset Seizures Phase 1 oral Northwestern University
Tuberous Sclerosis Complex Phase 1 oral Northwestern University
Infantile Spasms Phase 1 oral Northwestern University
Undisclosed indication Northwestern University

OV4071

Small Molecule Target: KCC2

Undisclosed indication Phase 1 oral AstraZeneca
Undisclosed indication Phase 1 AstraZeneca

Technology platforms

KCC2 Direct Activator Library · AstraZeneca

Portfolio of more than 100 small molecules that directly activate the KCC2 potassium-chloride cotransporter, exclusively expressed in the CNS. Programs emerging from the library are being evaluated for psychosis, schizophrenia, mood disorders, and seizures, including neurodegenerative and neurodevelopmental conditions. In-licensed from AstraZeneca in 2021.

Targets: KCC2

Gensaic Intracellular Delivery Platform · Gensaic

Proprietary tissue-selective intracellular delivery platform for genetic medicines targeting neurological indications. Collaboration with Gensaic to potentially develop up to three genetic medicines for neurological indications of interest to Ovid.

Gensaic PDP Platform · Gensaic

Gensaic's proprietary phage-derived particle (PDP) platform for rare central nervous system (CNS) disorder targets; Ovid holds an option to obtain an exclusive license for identified lead PDP products.

Discontinued (1)

OV350 — undisclosed · Company elected to prioritize oral direct activator programs; does not intend to advance OV350 further in the clinic

Biotech Distilled coverage (4)

2026-05-12 UPDATE: Ovid Therapeutics (OVID) - The KCC2 Switch Gets Flipped (in a Human) 🔒 Paid
2026-04-27 UPDATE: Ovid Therapeutics (OVID) - The Warrants Print, the CEO Changes, the Thesis Tightens 🔒 Paid
2026-03-22 UPDATE: Ovid Therapeutics (OVID) - $60M Double Down and the Death of the Dilution Gap 🔒 Paid
2026-01-27 Ovid Therapeutics (OVID): Scientific Deep Dive for OV329 and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.